Navigation Links
Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Date:3/7/2008

877-852-6578 (U.S.), 1-719-325-4794 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401, which is currently in Phase 2 clinical development for multiple tumor types, is expected to move into a Phase 3 clinical program in 2008. The Company also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates.

Cautionary Statement

As the Company has indicated in its public filings, among other things, clinical trials have a high risk of failure. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in advanced clinical trials, even after achieving what appeared to be promising results in earlier trials.

Furthermore, as indicated in previous fili
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... The Eastern European medical device industry is ... well as new medical-device manufacturers are constantly trying to ... ways to reduce the cost incurred for placing their ... the effective means to achieve this target. This research ... European and provides profiles of key distributors in ...
(Date:9/30/2014)... Sept. 30, 2014 Passport Health, one of ... , has launched FluFree.com, a website designed to promote, ... For 20 years, Passport Health has provided its ... The launch of FluFree.com is designed to address the ... number of people who actually chose to get vaccinated. ...
(Date:9/30/2014)... MUNSTER, Ind. , Sept. 30, 2014  The orthopedic ... ranked the nation,s No. 6 orthopedic group by US ... for Active Adults," a series of free, public seminars ... from all over the world come to see the ... replacement procedures are now available at Munster Specialty Surgery ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2
... Feb. 27, 2012  GP Strategies Corporation (NYSE: ... provider of sales and technical training, e-Learning solutions, management ... Greenberg and CFO Sharon Esposito-Mayer will speak at the ... 2012, at 10:55 a.m. ET. The conference will be ...
... 27, 2012 Nektar Therapeutics (Nasdaq: NKTR ) ... its new oral opioid analgesic molecule, at the 2012 American ... a novel mu-opioid agonist molecule, which was designed to have ... the attractiveness of the molecule as a target of abuse ...
Cached Medicine Technology:Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 2Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 3Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 4Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 5Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 6Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 7Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 8Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 9Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 10
(Date:10/1/2014)... October 01, 2014 The Oliver ... a new Other-Sonic Ultrasound Gel lawsuit web ... about the litigation surrounding the 2011 Pseudomonas aeruginosa ... in Royal Oak, Michigan, which was ultimately traced ... is representing William Beaumont patients who allegedly became ...
(Date:10/1/2014)... MI (PRWEB) October 01, 2014 To help ... wellness center , Cutler Integrative Medicine, is detailing several tips ... , According to Dr. Cutler, women should start ... quality time for yourself that will help ‘center’ yourself for ... of stress,” he says. , Other health and fitness ...
(Date:9/30/2014)... third of medical and nursing students in developing countries ... countries after graduation, while less than one fifth of ... are needed most, according to a new study. , ... the current outbreak of Ebola in western Africa. The ... of the world,s poorest countries (Guinea, Sierra Leone and ...
(Date:9/30/2014)... carbon emissions will reduce other harmful air pollution ... a new study released today. The research shows ... the final Clean Power Plan, the power plant ... hospitalizations, and hundreds of heart attacks in the ... Health Co-benefits of Carbon Standards for Existing Power ...
(Date:9/30/2014)... stranger to the children of Tanzania. What is rare ... services, including reliable diagnosis and evidence-based treatments. There is ... in Swahili, a major language of the region. In ... and the University of Georgia (UGA) describe a culturally ... in the country and found to be effective for ...
Breaking Medicine News(10 mins):Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 2Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 4Health News:In Recognition of National Women’s Health and Fitness Day, Cutler Integrative Medicine Details Tips for Living a Healthier and Happier Life 2Health News:Developing countries should enroll medical and nursing students from rural areas 2Health News:Developing countries should enroll medical and nursing students from rural areas 3Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4
... There is an increasing number of HIV cases reported among ... by the Centre for disease control and prevention (CDC) and ... sharing and using the same needle up to 15 times ... ,The researchers are very worried and discussed about ...
... have found that a protein known for driving the ... restoring the ability of neurons to regenerate // , ... damage or neurological diseases like Alzheimers., ,"The finding ... proliferating cancer could also potentially be used to regrow ...
... help people lose weight, will be launched in the UK.This ... that controls //the desire to over-eat and it has been ... worldwide to have access to the medication. ,It ... loss by blocking the brain's craving signals, thereby suppressing the ...
... vaccination experts have written an open letter in the Scotsman ... the rumors// that MMR Vaccine was linked to autism. ... taken, the UK could face a serious situation with outbreaks ... questions of "any association between MMR and autism" should be ...
... contraceptive pill intended for consumption without a break is ... The pill, named Anya, manufactured by Wyeth Pharmaceuticals, is ... to give a merry slip to the monthly period! ... is undergoing a testing period marked by extensive clinical ...
... of transplant surgeries, doctors are rethinking on the guidelines ... (AHEC) is deliberating //over the permission for medical procedures ... on the ventilator, with a motive to remove organs ... the issue of removal of organs from the patient ...
Cached Medicine News:Health News:Wonder Drug For Weight Loss Launched In UK 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: